Finding ovarian or endometrial cancer early can change a life. This study looked at 238 women seen at three major hospitals between 2018 and 2023. Researchers tested cervicovaginal swabs to find specific genetic changes. They compared women with cancer to those with benign conditions. The goal was to see if these markers could accurately identify the disease.
The results showed that TP53 mutations appeared in 68 percent of cancer samples. PTEN mutations were found in 47 percent of those same samples. These genetic changes are signs of cancer cells growing. The study also looked at DNA methylation markers alongside these genetic mutations. Together, these markers showed promise for spotting the disease.
However, the researchers noted that more forward-looking studies are needed. They called for further prospective investigation to confirm these findings in real time. This means we cannot yet say this test is ready for everyone. It remains a potential tool that needs more testing before doctors use it widely for surveillance.